CCL2 and acute myeloid leukemia: The expression of markers such as FOXP3, CD274, LGALS1, CCL2, CCL5, IL2RA, LAG3, TNFRSF18, and HAVCR2 were upregulated in the AML group, indicating that immune modulation processes were activated, potentially influencing T cell activation, differentiation, migration, and checkpoint signaling, and thereby reshaping the immune landscape within the leukemic microenvironment (Figure 7B).